An Open-label Phase I, Dose Escalation Study of the Safety and Tolerability of OPD5 as Myeloablative Conditioning Regimen Followed by Autologous Stem Cell Transplant (ASCT) for Patients With Relapsed Refractory Multiple Myeloma (RRMM)
Latest Information Update: 02 Dec 2021
At a glance
- Drugs OPD 5 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Acronyms COAST
- Sponsors Oncopeptides
- 17 Nov 2021 Status changed from suspended to withdrawn prior to enrolment. Sponsor made the decision to terminate the COAST study to refocus the OPD5 clinical program.
- 09 Jul 2021 Status changed from recruiting to suspended (The study has been temporarily suspended while awaiting further analysis of data from othertrials).
- 04 Jun 2021 Status changed from planning to recruiting.